Group 1 - The core index, the CESHKB, increased by 1.74% to 9852.81 points with a trading volume of 14.774 billion [1] - The CESHKB index has risen by 20.92% in the past month, 69.27% in the past three months, and 116.13% year-to-date [1] - The index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd. and aims to reflect the overall performance of biotechnology companies listed in Hong Kong [1] Group 2 - The top ten weighted stocks in the CESHKB index include: - CanSino Biologics (13.72%) - Innovent Biologics (9.48%) - 3SBio (8.99%) - WuXi Biologics (8.61%) - BeiGene (8.53%) - WuXi AppTec (6.93%) - Kintor Pharmaceutical (4.94%) - Zai Lab (4.28%) - Nuo Therapeutics (4.1%) - Genscript Biotech (3.78%) [1] - The CESHKB index is entirely composed of stocks listed on the Hong Kong Stock Exchange, with 100% allocation [2] - The index's holdings are exclusively in the healthcare sector, with 100% allocation to the pharmaceutical and healthcare industry [2]

Group 1 - The core index, the CESHKB, increased by 2.22% to 9684.5 points with a trading volume of 19.513 billion [1] - The CESHKB index has risen by 21.28% over the past month, 67.37% over the past three months, and 111.44% year-to-date [1] - The index is designed to reflect the overall performance of biotechnology companies listed in Hong Kong, with a base date of December 12, 2014, and a base point of 2000.0 [1] Group 2 - The top ten holdings of the CESHKB index include: - CanSino Biologics (13.85%) - Innovent Biologics (9.49%) - WuXi Biologics (8.72%) - 3SBio (8.71%) - BeiGene (8.39%) - WuXi AppTec (7.03%) - Kintor Pharmaceutical (5.02%) - Zai Lab (4.33%) - Nuo Therapeutics (3.91%) - Kingstar Biotech (3.8%) [1] - The CESHKB index is fully composed of companies listed on the Hong Kong Stock Exchange, with 100% of its holdings in the healthcare sector [2]

据了解，"中华交易服务香港生物科技指数由中华证券交易服务有限公司(中华交易服务)委托中证指数 有限公司(中证指数)进行编制，指数编制方案由中华交易服务以及中证指数共同确定。中华交易服务香 港生物科技指数(中华香港生物科技)为证券价格指数，旨在反映于香港上市的生物科技公司的整体表 现"该指数以2014年12月12日为基日，以2000.0点为基点。 从指数持仓来看，中华交易服务香港生物科技指数十大权重分别为：康方生物（13.31%）、信达生物 （9.84%）、三生制药（9.12%）、百济神州（8.94%）、药明生物（8.9%）、药明康德（5.65%）、科 伦博泰生物-B（4.91%）、再鼎医药（4.82%）、诺诚健华-B（4.34%）、金斯瑞生物科技（4.0%）。 金融界7月21日消息，上证指数高开高走，中华交易服务香港生物科技指数 (中华香港生物科技， CESHKB)下跌1.62%，报8758.46点，成交额121.71亿元。 数据统计显示，中华交易服务香港生物科技指数近一个月上涨21.79%，近三个月上涨64.09%，年至今 上涨98.69%。 从中华交易服务香港生物科技指数持仓的市场板块来看，香港证券交易所 ...

Group 1 - The A-share market showed mixed results with the Chinese Securities Trading Service Hong Kong Biotechnology Index (CESHKB) declining by 2.61% to 7650.23 points, with a trading volume of 9.469 billion [1] - Over the past month, the CESHKB has increased by 15.23%, 28.86% over the last three months, and 75.31% year-to-date [1] - The CESHKB is compiled by the China Securities Index Co., Ltd. under the commission of the China Securities Trading Service Co., Ltd., aiming to reflect the overall performance of biotechnology companies listed in Hong Kong [1] Group 2 - The top ten holdings of the CESHKB include: CanSino Biologics (12.33%), Innovent Biologics (9.95%), WuXi Biologics (9.17%), 3SBio (8.66%), BeiGene (8.57%), Zai Lab (5.79%), WuXi AppTec (5.63%), Kelun-Biotech (5.28%), Ascentage Pharma-B (4.19%), and Kingstar Biotech (4.11%) [1] - The CESHKB's holdings are entirely composed of companies listed on the Hong Kong Stock Exchange, with a 100% representation in the healthcare sector [2]

Core Viewpoint - The CESHKB index has shown significant growth, with a year-to-date increase of 64.30%, indicating a strong performance in the biotechnology sector listed in Hong Kong [1][2]. Group 1: Index Performance - The CESHKB index opened high and fluctuated, closing at 7388.22 points with a trading volume of 12.985 billion [1]. - Over the past month, the CESHKB index has risen by 14.05%, and over the last three months, it has increased by 17.80% [1]. Group 2: Index Composition - The CESHKB index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd., reflecting the overall performance of biotechnology companies listed in Hong Kong [1]. - The top ten holdings in the CESHKB index include: - CanSino Biologics (10.49%) - Innovent Biologics (9.9%) - WuXi Biologics (9.73%) - 3SBio (8.86%) - BeiGene (8.81%) - Zai Lab (5.86%) - WuXi AppTec (5.85%) - Kelun-Biotech (5.1%) - Genscript Biotech (4.42%) - Ascentage Pharma-B (4.15%) [1]. Group 3: Market and Industry Overview - The CESHKB index is entirely composed of companies listed on the Hong Kong Stock Exchange, with a 100% representation in the healthcare sector [2].

Group 1 - The core index, the CESHKB, increased by 2.7% to 7293.11 points with a trading volume of 11.568 billion [1] - The CESHKB has risen by 15.52% in the past month, 19.54% in the past three months, and 58.49% year-to-date [1] - The index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd. and aims to reflect the overall performance of biotechnology companies listed in Hong Kong [1] Group 2 - The top ten weighted stocks in the CESHKB include: CanSino Biologics (10.91%), Innovent Biologics (9.99%), BeiGene (9.73%), WuXi Biologics (9.42%), 3SBio (8.11%), Zai Lab (6.05%), WuXi AppTec (5.56%), Kelun-Biotech (5.15%), Kingstar Bio (4.37%), and Ascentage Pharma-B (3.89%) [1] - The CESHKB is entirely composed of stocks listed on the Hong Kong Stock Exchange, with a 100% allocation [2] - The index's holdings are exclusively in the healthcare sector, specifically in pharmaceuticals and biotechnology, also at a 100% allocation [2]

Core Points - The Hong Kong Biotechnology Index (CESHKB) experienced a decline of 3.05%, closing at 7087.18 points with a trading volume of 11.816 billion [1] - Over the past month, the index has increased by 26.57%, by 25.92% over the last three months, and has risen 63.14% year-to-date [1] - The index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd. and aims to reflect the overall performance of biotechnology companies listed in Hong Kong [1] Index Composition - The top ten weighted stocks in the index include: - CanSino Biologics (10.86%) - Innovent Biologics (10.22%) - WuXi Biologics (9.54%) - BeiGene (9.36%) - 3SBio (7.95%) - Zai Lab (6.01%) - WuXi AppTec (5.63%) - Kelun-Biotech (5.20%) - Genscript Biotech (4.44%) - Ascentage Pharma-B (3.91%) [1] Market and Industry Overview - The index's holdings are entirely composed of stocks listed on the Hong Kong Stock Exchange, with a 100% representation in the pharmaceutical and healthcare sector [2]

Group 1 - The core index, the CESHKB, increased by 1.98% to 5775.66 points, with a trading volume of 6.408 billion [1] - Over the past month, the CESHKB has risen by 7.34%, by 17.05% over the last three months, and by 28.90% year-to-date [1] - The CESHKB is designed to reflect the overall performance of biotechnology companies listed in Hong Kong, with a base date of December 12, 2014, set at 2000.0 points [1] Group 2 - The top ten holdings of the CESHKB include: Innovent Biologics (10.8%), CanSino Biologics (10.42%), WuXi Biologics (10.27%), China National Pharmaceutical Group (9.64%), BeiGene (9.22%), Kelun-Biotech (5.32%), Zai Lab (5.26%), WuXi AppTec (5.16%), 3SBio (5.15%), and Genscript Biotech (3.23%) [1] - The CESHKB is fully composed of companies listed on the Hong Kong Stock Exchange, with 100% representation [2] - The industry representation of the CESHKB is entirely in the healthcare sector, specifically pharmaceuticals and biotechnology, also at 100% [2]

Group 1 - The core index of the China Securities Exchange Service Hong Kong Biotechnology Index (CESHKB) rose by 4.86%, closing at 5646.67 points with a trading volume of 10.416 billion [1] - Over the past month, the CESHKB has decreased by 1.72%, but it has increased by 28.09% over the last three months and by 20.18% year-to-date [1] - The CESHKB is designed to reflect the overall performance of biotechnology companies listed in Hong Kong, with a base date of December 12, 2014, and a base point of 2000.0 [1] Group 2 - The top ten holdings of the CESHKB include: CanSino Biologics (11.2%), Innovent Biologics (10.58%), BeiGene (10.28%), WuXi Biologics (9.54%), China National Pharmaceutical Group (9.18%), Zai Lab (5.76%), 3SBio (5.37%), Kelun-Biotech (4.59%), WuXi AppTec (4.46%), and Genscript Biotech (3.47%) [1] - The CESHKB is fully composed of stocks listed on the Hong Kong Stock Exchange, with a sector breakdown showing that biopharmaceuticals account for 60.95%, pharmaceutical and biotechnology services for 22.57%, chemical drugs for 12.94%, and medical devices for 3.53% [2]